- Home
- PEBO vs IOVA Comparison
PEBO vs IOVA Comparison
Compare PEBO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEBO
- IOVA
- Stock Information
- Founded
- PEBO 1902
- IOVA 2007
- Country
- PEBO United States
- IOVA United States
- Employees
- PEBO N/A
- IOVA N/A
- Industry
- PEBO Major Banks
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PEBO Finance
- IOVA Health Care
- Exchange
- PEBO Nasdaq
- IOVA Nasdaq
- Market Cap
- PEBO N/A
- IOVA 1.0B
- IPO Year
- PEBO N/A
- IOVA N/A
- Fundamental
- Price
- PEBO $29.63
- IOVA $1.75
- Analyst Decision
- PEBO Buy
- IOVA Strong Buy
- Analyst Count
- PEBO 6
- IOVA 9
- Target Price
- PEBO $36.67
- IOVA $15.50
- AVG Volume (30 Days)
- PEBO 147.1K
- IOVA 13.9M
- Earning Date
- PEBO 04-22-2025
- IOVA 05-08-2025
- Dividend Yield
- PEBO 5.53%
- IOVA N/A
- EPS Growth
- PEBO N/A
- IOVA N/A
- EPS
- PEBO 3.15
- IOVA N/A
- Revenue
- PEBO $561,241,000.00
- IOVA $212,679,000.00
- Revenue This Year
- PEBO N/A
- IOVA $182.20
- Revenue Next Year
- PEBO $3.92
- IOVA $62.10
- P/E Ratio
- PEBO $9.42
- IOVA N/A
- Revenue Growth
- PEBO 12.39
- IOVA 11070.12
- 52 Week Low
- PEBO $26.21
- IOVA $2.70
- 52 Week High
- PEBO $37.07
- IOVA $13.60
- Technical
- Relative Strength Index (RSI)
- PEBO 57.07
- IOVA 23.78
- Support Level
- PEBO $28.82
- IOVA $3.02
- Resistance Level
- PEBO $29.80
- IOVA $3.31
- Average True Range (ATR)
- PEBO 0.64
- IOVA 0.24
- MACD
- PEBO 0.18
- IOVA -0.09
- Stochastic Oscillator
- PEBO 90.15
- IOVA 4.81
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.